Transcranial Direct Current Stimulation in Children With Autism

Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age5-12
SponsorNew York State Institute for Basic Research

About this trial

Although many children diagnosed with autism spectrum disorder (ASD) make significant progress in learning and their cognitive skills improve with applied behavior analysis (ABA), there are a significant number of children who show an absence or a plateau in various skills. Deficits in executive functioning are likely to be involved in many of these cognitive and learning disabilities due to poor functioning of the prefrontal cortex. Currently, the use of biological methods for improving learning and cognition is largely unexplored in research and practice.

The aim of this study is to use of transcranial direct current stimulation (tDCS) in combination with ABA to improve the acquisition of educational programs for students with ASD. tDCS is a low-level electrical neurostimulation and is most effective when used in combination with an active training or teaching, facilitating the neuronal circuits used for that task.

tDCS has been used for various indications over a couple of decades and has been shown to be very safe and has been well-tolerated by children with ASD. The mechanism of tDCS is not clear, however animal studies show that tDCS can stimulate the flow of calcium ions through channels in the astrocytes, activating them, and facilitating their role in synapse formation and therefore learning.

Eligibility criteria

Qualifiers

Males and females between 5 and 12 years with autism

Enrolled in an ABA program (school or in-home) supervised by a Board Certified Behavior Analyst (BCBA)

Stable medical and behavioral treatments for at least 4 weeks prior to, and during the study

Able to tolerate wearing tDCS as determined during a week-long daily desensitization training.

Disqualifiers

Any implanted metal device (heart pacemaker, cochlear implant, surgical clips, etc.)

Severe neurological disorders such as TBI, brain tumor, intracranial infection

Seizure disorder with a seizure within the last two years

Skull defect

Trial design

Treatments tested in this trial

  • Active tDCS
  • Sham (No Treatment)

Treatment groups

24 Participants
are divided into 2 treatment groups